Phaseline

Companies › Nuvalent

Nuvalent: clinical trials, targets and expected readouts

3 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 3; Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Neladalkib (NVL-655)
ALK inhibitor
ALKPhase 3Non-small Cell Lung Cancer; Locally Advanced Solid TumorDec 2027
NVL-330
HER2 tyrosine kinase inhibitor
ERBB2Phase 1Locally Advanced Solid TumorJan 2027
Zidesamtinib (NVL-520)
ROS1 inhibitor
ROS1Phase 1Locally Advanced Solid TumorDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06521554NVL-330Phase 1Locally Advanced Solid TumorOncologyJan 2027
NCT05384626Neladalkib (NVL-655)Phase 1Locally Advanced Solid TumorOncologyDec 2027
NCT05118789Zidesamtinib (NVL-520)Phase 1Locally Advanced Solid TumorOncologyDec 2027
NCT06765109Neladalkib (NVL-655)Phase 3Non-small Cell Lung CancerOncologyDec 2029

Specialist investors

Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

ERBB2 (1) ALK (1) ROS1 (1)

Companies with the same targets

Roche Beijing Biotech Pfizer Jiangsu HengRui Medicine Shenyang Sunshine Pharmaceutical Suzhou Suncadia Biopharmaceuticals Sichuan Baili Pharmaceutical Shanghai Henlius Biotech Chia Tai Tianqing Pharmaceutical Group Yuhan

Companies built like this

SystImmune Shenzhen TargetRx CStone Pharmaceuticals DualityBio Aston Sci.

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.